A Phase 4 interventional study of Warfarin and Warfarin 5mg + Rosuvastatin 40 mg once daily (QD) in Healthy, sponsored by Kowa Research Institute, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-08.
Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 4 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 4, single center, open label, 4 period, 2 treatment, crossover, drug-drug interaction study.
Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Warfarin · Drug: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD) · Drug: Warfarin 5 mg + Pitavastatin 4mg once daily (QD)
Drug: Warfarin · Drug: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD) · Drug: Warfarin 5 mg + Pitavastatin 4mg once daily (QD)
Percent Mean Change From Baseline of International Normalized Ratio (INR)
INR is the ratio of a patient's prothrombin time to a standard, raised to the power of the ISI value for the tissue factor reagent used (INR = (PT-Test/PT-Normal)\^ISI)
Time frame: 22 Days
14 July 2010 - 09 November 2010
| Milestone | Pitavastatin/Rosuvastatin | Rosuvastatin/Pitavastatin |
|---|---|---|
| Started | 24 | 24 |
| Completed | 23 | 22 |
| Not completed | 1 | 2 |
| Withdrew: Inr out of range | 1 | 2 |
| Milestone | Pitavastatin/Rosuvastatin | Rosuvastatin/Pitavastatin |
|---|---|---|
| Started | 23 | 22 |
| Completed | 22 | 22 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | Pitavastatin/Rosuvastatin | Rosuvastatin/Pitavastatin |
|---|---|---|
| Started | 22 | 22 |
| Completed | 21 | 22 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | Pitavastatin/Rosuvastatin | Rosuvastatin/Pitavastatin |
|---|---|---|
| Started | 21 | 22 |
| Completed | 21 | 19 |
| Not completed | 0 | 3 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
INR is the ratio of a patient's prothrombin time to a standard, raised to the power of the ISI value for the tissue factor reagent used (INR = (PT-Test/PT-Normal)\^ISI)
| percent change | Warfarin + Pitavastatin | Warfarin + Rosuvastatin |
|---|---|---|
| Percent Mean Change From Baseline of International Normalized Ratio (INR) | 0.0452 ± 2.61 | 0.1605 ± 9.43 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Warfarin + Pitavastatin | — | 0/42 (0%) | 6/42 (14.3%) |
| Warfarin + Rosuvastatin | — | 0/43 (0%) | 3/43 (7%) |
| Event | Warfarin + Pitavastatin | Warfarin + Rosuvastatin |
|---|---|---|
| NauseaGastrointestinal disorders | 3/42 | 3/43 |
| HeadacheNervous system disorders | 3/42 | 0/43 |
| Age, Categorical(Participants) | Pitavastatin/Rosuvastatin | Rosuvastatin/Pitavastatin | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 24 | 24 | 48 |
| >=65 years | 0 | 0 | 0 |
| Age Continuous(years) | Pitavastatin/Rosuvastatin | Rosuvastatin/Pitavastatin | Total |
|---|---|---|---|
| Mean | 32.4 ± 7.8 | 34.1 ± 7.2 | 33.3 ± 7.5 |
| Sex: Female, Male(Participants) | Pitavastatin/Rosuvastatin | Rosuvastatin/Pitavastatin | Total |
|---|---|---|---|
| Female | 8 | 8 | 16 |
| Male | 16 | 16 | 32 |
| Region of Enrollment(participants) | Pitavastatin/Rosuvastatin | Rosuvastatin/Pitavastatin | Total |
|---|---|---|---|
| United States | 24 | 24 | 48 |
The record gives a start of Jul 2010, a primary completion of Oct 2010 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Warfarin
Kowa Research Institute, Inc. →